Visterra Obtains $30,000,000 Series B Funding

  • Feed Type
  • Date
    10/2/2014
  • Company Name
    Visterra
  • Mailing Address
    One Kendall Square Cambridge, MA 02139 USA
  • Company Description
    Visterra, Inc. is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. The Company focuses on technologies that can interrogate how pathogens interact with human cells, a critical first step in the disease process.
  • Website
    http://www.visterrainc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used to advance the development of multiple product candidates from the company’s pipeline of novel monoclonal antibodies that target infectious diseases, including VIS410 for seasonal and pandemic influenza and VIS513 for dengue fever, into the clinic.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy